| FORM 4 | 4 |
|--------|---|
|--------|---|

| Check this box if no | | | | | |
|-----------------------|--|--|--|--|--|
| longer subject to | | | | | |
| Section 16. Form 4 or | | | | | |
| Form 5 obligations | | | | | |
| may continue. See | | | | | |
| Instruction 1(b). | | | | | |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

02)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type Responses) | | | - | | | | | | | | |
|---|---|---------------------|--|--------------------|-----------|--|--|------------|---|----------------------------------|-------------------------|
| 1. Name and Address of Rep Shenouda Maged | 2. Issuer Name and Ticker or Trading Symbol RELMADA THERAPEUTICS, INC. [RLMD] | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | |
| (Last) (Fi C/O RELMADA THER THIRD AVENUE, SUI | APEUTICS, IN | · · | 3. Date of Earliest Transaction (Month/Day/Year) 12/15/2015 | | | | | | Officer (give title below) | Other (specify b | pelow) |
| (Street) NEW YORK, NY 10017 | | | 4. If Amendment, Date Original Filed(Month/Day/Year) | | | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person | | |
| (City) (St | ate) (Z | Zip) | Tab | le I - Non-l | Deri | vative Se | red, Disposed of, or Beneficially Owned | | | | |
| 1.Title of Security (Instr. 3) | 2. Transa Date (Month/I | action Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Code (Instr. 8) | tion | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | of | eneficially Owned Following eported Transaction(s) nstr. 3 and 4) Ownership Form: Direct (D) | | Beneficial Ownership |
| | | | | Code | V | Amount | (A) or (D) | Price | | or Indirect (I) (Instr. 4) | (Instr. 4) |
| Common stock | 12/15/2 | 015 | | Р | | 2,000 | А | \$ 2.98 | 4,000 | D | |
| Common stock | 12/15/2 | 015 | | Р | | 241 | А | \$ 2.99 | 4,241 | D | |
| Common stock | 12/15/2 | 015 | | Р | 759 A \$3 | | \$3 | 5,000 | D | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

| (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | |
|--|-------------|------------------|--------------------|-------------|------|---------|-----|--------------|--------------------|--------|---------|-------------|----------------|-------------|-------------|
| 1. Title of | 2. | 3. Transaction | 3A. Deemed | 4. | 5. | Num | ber | 6. Date Exer | rcisable | 7. Tit | le and | 8. Price of | 9. Number of | 10. | 11. Nature |
| Derivative | Conversion | Date | Execution Date, if | Transaction | n of | | | and Expirati | on Date | Amo | unt of | Derivative | Derivative | Ownership | of Indirect |
| Security | or Exercise | (Month/Day/Year) | any | Code | De | erivat | ive | (Month/Day | /Year) | Unde | rlying | Security | Securities | Form of | Beneficial |
| (Instr. 3) | Price of | | (Month/Day/Year) | (Instr. 8) | Se | ecuriti | ies | | | Secu | rities | (Instr. 5) | Beneficially | Derivative | Ownership |
| | Derivative | | | | A | cquire | ed | | | (Instr | . 3 and | | | Security: | (Instr. 4) |
| | Security | | | | (A | () or | | | | 4) | | | Following | Direct (D) | |
| | | | | | Di | ispose | ed | | | | | | Reported | or Indirect | |
| | | | | | of | (D) | | | | | | | Transaction(s) | (I) | |
| | | | | | (II | nstr. 3 | , | | | | | | (Instr. 4) | (Instr. 4) | |
| | | | | | 4, | and 5 | 5) | | | | | | | | |
| | | | | | | | | | | | Amount | | | | |
| | | | | | | | | Date | Emination | | or | | | | |
| | | | | | | | | Exercisable | Expiration Date | Title | Number | | | | |
| | | | | | | | | Excicisable | Date | | of | | | | |
| | | | | Code V | r (A | A) (| D) | | | | Shares | | | | |

Reporting Owners

| | Relationships | | | | | | | |
|--|---------------|-----------|---------|-------|--|--|--|--|
| Reporting Owner Name / Address | Director | 10% Owner | Officer | Other | | | | |
| Shenouda Maged C/O RELMADA THERAPEUTICS, INC. 757 THIRD AVENUE, SUITE 2018 NEW YORK, NY 10017 | Х | | | | | | | |

Signatures

| /s/ Maged Shenouda | 12/17/2015 |
|----------------------------------|------------|
| ***Signature of Reporting Person | Date |

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.